OsteoMiR -- a novel disease-modifying drug for the treatment of osteoarthritis.

OsteoMiR——一种用于治疗骨关节炎的新型疾病缓解药物。

• 批准号: 74975
• 金额: $ 21.61万
• 依托单位: UNIVERSITY OF GLASGOW
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=74975
• 关键词: OsteoMiR; novel; disease; modifying; drug

Osteoarthritis (OA) is the leading cause of disability in older adults with 1 in 8 being affected. Around 75% of people with OA report constant pain, with approximately 30% giving up work or reducing the number of hours they work due to the condition. The cost of OA in the USA and Europe has been estimated at 1-2.5% of GDP. Currently, there are no Disease-Modifying OA Drugs (DMOAD). Loss of cartilage is believed to be a major cause of osteoarthritis symptoms and therefore, therapies that limit or reverse this damage are likely to reduce symptoms and benefit patients. Causeway Therapeutics is developing a treatment that uniquely targets the cellular pathways that drive the development of OA stopping disease progression, restoring function and reducing pain.

骨关节炎（OA）是老年人残疾的主要原因，每8人中就有1人受到影响。大约75%的OA患者报告持续疼痛，大约30%的人因病情而放弃工作或减少工作时间。在美国和欧洲，OA的成本估计为GDP的1-2.5%。目前，没有疾病修饰OA药物（DMOAD）。软骨损失被认为是骨关节炎症状的主要原因，因此，限制或逆转这种损伤的疗法可能会减轻症状并使患者受益。Causeway Therapeutics正在开发一种独特的治疗方法，该方法针对驱动OA发展的细胞通路，阻止疾病进展，恢复功能和减轻疼痛。